“Recurrent glioblastoma is a leading brain malignancy with few therapeutic options.”
“Here we present the complete results of a phase 1 trial investigating the safety and efficacy of autologous B7-H3-targeting chimeric antigen receptor T (CAR-T) cell (TX103) therapy for the treatment of recurrent glioblastoma.”
‘
“……patients aged 18–75 years with B7-H3-positive recurrent glioblastoma received intracranial infusion of TX103 at three dose levels…”
‘
“15 patients received a total of 72 intracranial infusions and 13 underwent repeated infusions.”
‘
“The 12-month overall survival rate was 66.7% and median was 19.1 months….”
“Disease control (stable disease or better) was achieved in 8 of 14 patients with measurable disease, including one complete response sustained through the latest follow-up.”
‘
Y. Zhang, et al
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial
Nature Medicine — Volume 32 #9 — September 2026 — page 3268